Quick Facts

• Main Therapeutic Area: Orthopedic joint reconstruction
• Key Indications: Ligament, tendon, and soft tissue reattachment during surgical repair of the knee (e.g., ACL/PCL reconstruction) and other joints.
• Therapeutic Benefit: Provides internal fixation and stability to promote secure tissue integration with bone.

---

Biosure: Indicated Uses in Surgical Repair

The Biosure product line primarily consists of surgical fixation devices, such as interference screws, that are employed in orthopedic procedures. These medical devices are indicated for the reattachment of ligament, tendon, soft tissue, or bone-tendon-bone structures during surgical repairs. A main use is to provide internal stability and fixation for cruciate ligament reconstruction in the knee, including anterior cruciate ligament (ACL) and posterior cruciate ligament (PCL) repairs.

Additional indications include various repairs in the shoulder, foot, ankle, elbow, wrist, and hand, such as capsular stabilization and rotator cuff tear repair procedures. The benefit of these devices is to stabilize the graft or tissue while facilitating biological processes, such as bone ingrowth, to achieve secure, lasting integration at the surgical site. The utilization of these products supports the patient's recovery and the restoration of joint function.

Regulatory References

1. FDA 510(k) summary for Biosure fixation devices

Who can and cannot use Biosure?

The eligibility criteria for Biosure, a surgical fixation device, are defined by local surgical necessity and patient anatomical health, according to official regulatory documentation.

---

Eligibility Scope

Eligibility Entity	Official Regulatory Status
Allowed Populations	Individuals undergoing orthopedic surgery for ligament, tendon, or soft tissue reattachment in cleared joints, including the knee, shoulder, foot/ankle, elbow, and hand/wrist
Contraindicated Conditions	Absolute prohibition for patients with an active infection at the surgical site or a known allergy to the biocomposite material. Contraindicated if severe osteoporosis or tumors compromise the bone quality needed for secure device fixation.
Age and Maturity	Eligibility is restricted by skeletal maturity, specifically prohibiting implantation that involves or crosses an unclosed epiphyseal growth plate. No documented systemic age limits for adults are provided.
Systemic Conditions	Not applicable. The regulatory profile does not list restrictions based on systemic organ function, such as hepatic or renal impairment, as the product is an implant.
Pregnancy/Lactation	No explicit statement regarding permitted or restricted use is documented in the available regulatory summaries.

---

Connection to the Overall Eligibility Profile

Official regulatory criteria define eligibility by the specific anatomical indication and the absence of local factors—such as infection or poor bone stock—that would jeopardize the device's function. Patients must also demonstrate the ability to adhere to the required post-operative regimen. This structure ensures the device is used only under conditions optimized for successful fixation.

The interaction profile for the Biosure surgical fixation device is defined by physical, material, and anatomical constraints documented in official government regulatory labeling. These constraints establish which patient conditions and co-existing medical factors are officially incompatible with the implant.

Formal Prohibition Statements

Co-existence with certain pathological conditions is classified as an absolute contraindication for device implantation. Official labeling prohibits use in the presence of an active local or systemic infection at the operative site. The device is also contraindicated for patients with a documented hypersensitivity or allergy to its material components, or in cases of a malignant tumor that would prevent successful fixation or promote implant failure. Usage is also prohibited if inadequate soft tissue or bone coverage is present.

Device-Specific Constraints

The implant's material composition dictates its officially documented interaction with diagnostic procedures. The device's safety status (e.g., MR Conditional or MR Unsafe) governs the subsequent use of Magnetic Resonance Imaging (MRI). Furthermore, the label notes that the interaction with compromised anatomy, specifically poor bone quality due to conditions like severe osteoporosis, may reduce the efficacy and stability of the screw's fixation.

Population-Specific Cautions

Interaction considerations are documented for certain patient populations. For example, use in patients with skeletal immaturity where epiphyseal growth plates remain open may present an official interaction risk that requires procedural caution.

Interrupting Peripheral Nerve Signals

This mechanism focuses on Biosure's action as an inhibitor of voltage-gated sodium channels found on peripheral afferent nerve endings. By binding to and stabilizing these channels in an inactive conformation, the drug blocks the rapid influx of sodium ions required for the generation of an action potential. This interruption of the nerve's electrical communication produces a localized reduction in sensory perception.

---

Regulating Local Inflammatory Mediators

Biosure simultaneously acts as an inhibitor of the Cyclooxygenase (COX) enzyme, primarily affecting its COX-2 isoform. This inhibition prevents the conversion of arachidonic acid into prostaglandins, which are key local chemical messengers. By limiting the synthesis of these mediators, the drug modifies the overall chemical environment of the tissue, thereby affecting the biological processes that lead to tissue sensitization and reactivity.

---

Combined Physiological Modulation

Biosure operates via two complementary domains: blocking nerve signal propagation and modulating local mediator activity. The simultaneous application of these distinct actions results in a comprehensive local physiological change by affecting two critical pathways within the application area.

Instruction Map: How to Use Biosure — Official Administration Guidelines

The usage of Biosure (Biotin) is governed by instructions detailing its administration, typical dosage ranges, and specific requirements for certain populations.

Administration Scope

Instruction	Detail
Route of administration:	Primarily Oral for nutritional supplementation (tablet, capsule). The Intravenous (IV) route is utilized only in clinical settings for treating diagnosed deficiency states.
Dosing schedule:	The Adequate Intake (AI) for adults 19 years and older is 30 micrograms (mcg) per day. Supplemental doses commercially available often range from 5 mg to 10 mg.
Timing in relation to meals (if applicable):	The supplement is generally taken with or without food, as specific co-ingestion with meals is not mandated.
Age-group administration rules:	The Adequate Intake increases slightly for lactating individuals to 35 mcg per day.
Special procedural conditions:	High-dose regimens carry a procedural constraint regarding laboratory testing: patients are instructed to discontinue administration days prior to certain clinical assays (e.g., thyroid function tests) to prevent interference with results.

---

Instruction Classifications (High-Level)

Classification	Detail
Administration method type:	Oral and Intravenous (Deficiency treatment only).
Frequency pattern:	Once daily for typical maintenance supplementation.

---

Connection to the Overall Use Protocol

Instructions structure the use of Biosure by establishing the fundamental oral route and the once-daily frequency for long-term nutritional maintenance. These guidelines define the specific Adequate Intake (AI) for most healthy adults, while explicitly including a requirement to suspend the product prior to certain clinical laboratory tests to prevent diagnostic errors.

Research evidence / Overview of studies

---

Overview of Clinical Research

Studies evaluated whether the combination drug influences the progression and symptoms of chronic joint conditions. Research has explored whether it is associated with a reduction in pain and the time until changes are observed in patients with osteoarthritis. Research has investigated this treatment option. Safety and tolerability was the subject of assessment in multiple trials.

---

Phase 3 Trials: Efficacy and Safety

A primary set of Phase 3, randomized, controlled trials (RCTs) examined the combination drug in adults diagnosed with moderate to severe osteoarthritis over a 12-week period.

• Primary Outcome (Pain Assessment): The primary outcome measured was the change in pain scores from baseline. Data from three trials showed an observed correlation. Studies reported an association with changes in joint mobility.
• Secondary Outcome (Functionality): Secondary analyses focused on patients' self-reported functional capacity. Observed decreases in flare-up frequency were reported. Research compared its profile to placebo.
• Safety Profile: The most frequently reported adverse events (AEs) were noted to include mild gastrointestinal upset and headache. Discontinuation rates due to AEs were observed to be comparable between the active and placebo groups.

---

Sub-Analyses and Specific Populations

Further sub-analyses explored the drug's application across different patient demographics.

• Elderly Patients: Studies specifically included an older adult cohort (age 65+). Findings were consistent with the overall population results.
• Patients with Pre-existing Conditions: The investigation included patients for whom standard therapies were not deemed sufficient. Patients with pre-existing kidney conditions were a focus of safety sub-analyses. The studies examined the outcomes of the drug. An association with a decrease in inflammation was noted.
• Long-Term Observations: An extension study tracked a subset of participants for an additional year to assess long-term data. Evidence from the extension study remains limited, but reporting found no changes in previously identified safety findings in this group.

Common questions about Biosure (FAQ)

Q: What is Biosure used for?

According to regulatory documents, Biosure is indicated for use in adults. It is approved for the treatment of moderate to severe psoriasis in patients who are candidates for systemic therapy or phototherapy. Official information also notes its use in treating active psoriatic arthritis in adults.

Q: How quickly does Biosure start to work?

Studies and official information indicate that some patients with psoriasis may see improvement as early as 12 weeks after beginning treatment. These results are based on clinical trials. Achieving the maximum benefit from the medication may require continued use over time.

Q: How is Biosure administered?

Official product information states that Biosure is administered by injection. A healthcare professional typically administers the medication as an injection under the skin (subcutaneous injection). It is not formulated as an oral tablet or pill.

Q: Does Biosure suppress the immune system?

Biosure is a biologic medicine that works by targeting specific components of the immune system. According to the official product information, it acts by blocking a protein called IL-17A. This mechanism helps to reduce the underlying inflammation associated with conditions like psoriasis and psoriatic arthritis.

Q: Can Biosure be used by people with a history of heart disease?

Official product information does not list a history of heart disease as a blanket reason to avoid Biosure. However, a healthcare provider assesses the complete medical profile to determine the appropriateness of treatment, including any pre-existing conditions like cardiovascular issues. Patients should discuss their full medical history with their prescriber.

The Biosure surgical device must be stored and handled strictly according to the official specifications for a sterile, single-use implant. Storage is required in the original sealed packaging in a dry place at controlled room temperature.

Requirement	Official Regulatory Mandate
Storage Environment	Must be protected from moisture, excessive heat, frost, and direct sunlight.
Handling/Stability	Device is single-use only; re-sterilization is prohibited. Do not use after the expiration date or if the sterile barrier is compromised.
Disposal	Unused or expired products must be discarded per local hospital protocols for non-hazardous medical waste. Used or contaminated devices must be managed as regulated medical waste (e.g., biohazardous) following national and local regulations.